On this page
TRDN
triadin
TRDN encodes triadin, a regulatory protein critical for controlled calcium release in cardiac and skeletal muscle contraction. The TRDN gene provides instructions for making triadin, a membrane-anchored protein that orchestrates calcium signalling in muscle cells.
TRDN is located on the long (q) arm of chromosome 6, at band 6q22.31. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 6 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The TRDN gene encodes triadin, a transmembrane protein integral to excitation-contraction coupling in both cardiac and skeletal muscle. Triadin serves as a molecular scaffold within the junctional sarcoplasmic reticulum, where it physically links ryanodine receptors to other regulatory proteins, ensuring that calcium ions are released in a coordinated manner when muscle cells receive electrical signals.
Pathogenic variants in TRDN follow an autosomal recessive inheritance pattern, meaning that two altered copies of the gene are typically required for disease manifestation. When both copies carry loss-of-function changes, the resulting deficiency in functional triadin protein disrupts calcium homeostasis, leading to clinical presentations that range from exercise-induced cardiac arrhythmias to early-onset muscle weakness. The gene is included in the American College of Medical Genetics and Genomics Secondary Findings list (version 3.2), reflecting the availability of medical interventions that can reduce sudden cardiac death risk in affected individuals.
What the gene does
Triadin functions as a regulatory component of the calcium-release machinery in muscle cells. The protein resides in the membrane of the sarcoplasmic reticulum, the specialised compartment that stores calcium ions. During muscle contraction, an electrical impulse triggers voltage-sensitive receptors in the cell membrane, which in turn signal ryanodine receptors to open channels in the sarcoplasmic reticulum membrane. Triadin stabilises the physical interaction between ryanodine receptors and calsequestrin, a calcium-binding protein within the sarcoplasmic reticulum lumen.
By anchoring calsequestrin near the ryanodine receptor complex, triadin ensures that calcium release is both rapid and precisely controlled. When intracellular calcium levels rise, calsequestrin senses this change and communicates back through triadin to modulate ryanodine receptor activity, preventing excessive calcium leak. This feedback loop is essential for maintaining the rhythm and force of muscle contractions. In cardiac tissue, proper triadin function helps coordinate the heartbeat, while in skeletal muscle it supports voluntary movement and endurance.
The protein's role extends beyond simple structural support. Research suggests that triadin participates in dynamic regulation of calcium cycling, influencing how quickly calcium is both released and resequestered during repeated contractions. Loss of triadin disrupts this delicate balance, leading to spontaneous calcium waves that can trigger abnormal electrical activity in the heart.
Video: Genetics 101
Chromosome location
TRDN is located on the long arm of chromosome 6 at cytogenetic band 6q22.31. This chromosomal region contains a cluster of genes involved in cellular signalling and structural organisation. The genomic span of TRDN includes multiple exons that encode the 729-amino-acid triadin protein, though the precise exon-intron architecture varies among different transcript isoforms. The gene's position at 6q22.31 places it within a genomically stable region, and no recurrent structural rearrangements affecting this locus have been widely reported in the literature.
Protein structure
The triadin protein comprises 729 amino acids and exhibits an unusual structural organisation characterised by extensive intrinsically disordered regions. Experimental data indicate that the majority of the polypeptide chain lacks stable secondary or tertiary structure under physiological conditions. Specifically, disordered regions span amino acids 1-28 at the N-terminal region, amino acids 117-265 in the central portion, a large stretch from amino acids 281-682, and the C-terminal segment from amino acids 705-729.
These disordered regions serve important biological functions; their flexibility allows triadin to interact with multiple binding partners simultaneously and to undergo conformational changes in response to cellular signals. The intrinsic disorder facilitates dynamic assembly and disassembly of protein complexes at the sarcoplasmic reticulum membrane. Between the disordered regions, short ordered segments are thought to mediate specific protein-protein interactions, including binding to ryanodine receptors and calsequestrin, though high-resolution structures of these interfaces have not been fully resolved.
Key variants
Pathogenic variants in TRDN are predominantly loss-of-function changes, including nonsense mutations, frameshift insertions or deletions, and splice-site alterations that result in absent or severely truncated protein. Because triadin functions within a multi-protein complex, even partial loss of the protein can destabilise calcium handling in muscle cells. Missense variants have also been reported, particularly those that disrupt key interaction surfaces required for binding to ryanodine receptors or calsequestrin.
The variant spectrum reflects the gene's autosomal recessive disease mechanism: individuals carrying a single pathogenic variant are typically asymptomatic carriers, while those inheriting two pathogenic alleles present with clinical disease. Founder effects have been observed in certain populations, where a specific TRDN variant recurs at higher frequency due to shared ancestry. Clinicians most commonly request TRDN genetic testing in the context of unexplained ventricular arrhythmias or early-onset myopathy, and identification of biallelic pathogenic variants confirms the molecular diagnosis.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.22+1G>T | - | Pathogenic | ★★☆☆ | Catecholaminergic polymorphic ventricular tachycardia 5 |
c.22+29A>G | - | Pathogenic | ★★☆☆ | Catecholaminergic polymorphic ventricular tachycardia 1 |
c.295dup | p.Thr99fs | Pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.2T>C | p.Met1Thr | Pathogenic | ★★☆☆ | Catecholaminergic polymorphic ventricular tachycardia 1 |
c.326del | p.Leu109fs | Pathogenic/Likely pathogenic | ★★☆☆ | Catecholaminergic polymorphic ventricular tachycardia 5 |
c.423del | p.Glu142fs | Pathogenic/Likely pathogenic | ★★☆☆ | Catecholaminergic polymorphic ventricular tachycardia |
c.438_442del | p.Asp146_Lys147insTer | Pathogenic | ★★☆☆ | not provided |
c.439_440del | p.Lys147fs | Pathogenic | ★★☆☆ | Cardiovascular phenotype |
c.483del | p.Val162fs | Pathogenic/Likely pathogenic | ★★☆☆ | Catecholaminergic polymorphic ventricular tachycardia 5 |
c.502G>T | p.Glu168Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Catecholaminergic polymorphic ventricular tachycardia 5 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Biallelic pathogenic variants in TRDN are associated with two principal clinical phenotypes, both reflecting the protein's central role in muscle calcium regulation. Catecholaminergic polymorphic ventricular tachycardia is a cardiac arrhythmia syndrome characterised by episodes of rapid, irregular heartbeat triggered by physical exertion or emotional stress. Affected individuals may experience palpitations, dizziness, or syncope, and in severe cases the arrhythmia can deteriorate into ventricular fibrillation and sudden cardiac death.
Congenital myopathy linked to TRDN variants typically presents in infancy or early childhood with muscle weakness, reduced muscle tone, and delayed motor milestones. The severity of muscle involvement varies, with some individuals experiencing mild weakness and others requiring respiratory support. Both cardiac and skeletal muscle manifestations can co-occur in the same individual, reflecting the widespread expression of triadin across muscle types.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic TRDN variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
TRDN is evaluated on multiple NHS Genomic Medicine Service gene panels, reflecting its clinical relevance in both cardiology and neuromuscular medicine. The gene holds green classification status on the Catecholaminergic Polymorphic VT panel (version R129), indicating strong evidence for its role in this arrhythmia syndrome and supporting its inclusion in diagnostic testing pathways for patients presenting with exercise-induced syncope or family history of sudden cardiac death. TRDN is also green-rated on the Congenital Myopathy panel (version R81), underpinning its use in the diagnostic workup of children and adults with unexplained muscle weakness or hypotonia. These panel memberships ensure that TRDN sequencing is available through the NHS when clinical criteria are met, facilitating early diagnosis and implementation of risk-reduction strategies.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
For individuals with confirmed biallelic TRDN variants and a diagnosis of catecholaminergic polymorphic ventricular tachycardia, general population research suggests that avoiding known arrhythmia triggers may help reduce the frequency of cardiac events. Strenuous physical exertion and acute emotional stress are recognised precipitants of ventricular arrhythmias in this context, and some clinical guidelines recommend structured exercise counselling and psychological support as part of comprehensive management.
In the setting of congenital myopathy related to TRDN variants, maintaining overall physical conditioning within safe limits may support functional independence, though specific exercise recommendations must be individualised. There is no evidence that dietary modifications directly alter the natural history of TRDN-related conditions, and any lifestyle adjustments should be discussed with a multidisciplinary care team that includes cardiology, neurology, and rehabilitation specialists as appropriate.
Supplement considerations
There is no conclusive evidence that any vitamin, mineral, or other dietary supplement can prevent or reverse the cardiac or skeletal muscle manifestations of TRDN-related disorders. Calcium and magnesium homeostasis are tightly regulated by cellular mechanisms, and oral supplementation does not meaningfully influence sarcoplasmic reticulum calcium handling in individuals with pathogenic TRDN variants. Some preliminary research has explored the potential role of antioxidants in supporting muscle health more broadly, but no specific benefits have been demonstrated for TRDN-associated myopathy.
Individuals considering any supplement should discuss this with their healthcare provider, particularly given the potential for interactions with antiarrhythmic or other cardiac medications that may be prescribed as part of arrhythmia management.
Frequently asked questions
What is the inheritance pattern for TRDN-related conditions?
TRDN-related conditions follow an autosomal recessive inheritance pattern, meaning an individual must inherit two pathogenic variants (one from each parent) to develop clinical disease. Carriers with a single pathogenic variant are typically unaffected.
Why is TRDN included in the ACMG Secondary Findings list?
TRDN is included in the ACMG Secondary Findings list (version 3.2) because pathogenic variants can cause life-threatening cardiac arrhythmias for which medical interventions, such as beta-blockers or implantable defibrillators, are available to reduce sudden death risk.
What types of symptoms might prompt TRDN genetic testing?
TRDN testing is typically considered when an individual experiences exercise-induced fainting, palpitations, or documented ventricular arrhythmias, or when a child presents with unexplained muscle weakness or delayed motor development. A family history of sudden cardiac death or congenital myopathy may also raise clinical suspicion.
Can TRDN variants affect both the heart and skeletal muscles?
Yes, because triadin is expressed in both cardiac and skeletal muscle, biallelic TRDN variants can lead to both cardiac arrhythmias and skeletal muscle weakness in the same individual, though the severity of each manifestation can vary.
Is genetic counselling recommended for families with TRDN variants?
Genetic counselling is strongly recommended for families in which a TRDN variant has been identified, as it helps clarify recurrence risk, guides family testing, and supports informed decision-making about cardiac screening and preventive interventions for at-risk relatives.